P17.15.A Neoadjuvant immunotherapy in the treatment of recurrent glioblastoma: an overview of last decade

alexandrossfakianakis shared this article with you from Inoreader P17.15.A Neoadjuvant immunotherapy in the treatment of recurrent glioblastoma: an overview of last decade via # Neuro-Oncology Current Issue Abstract Background Recurrent glioblastoma (ArGB) is one of the most common primary malignant brain tumors in adults, with a poor prognosis, with low patient survival even after treatment. Because of this, several studies were carried out evaluating different therapies for the treatment of ArGB, more recently studies have emerged regarding the use of neoadjuvant immunotherapy and its possible advantages in the treatment of such patients. Therefore, the present study aims to analyze the efficacy of neoadjuvant immunotherapy and its effect on the survival of patients with recurrent glioblastoma. Material and Methods A search was performed in PubMed, Embase and Cochrane databases using the keywords: "Immunotherapy, "neoadjuvant" and "recurrent glioblastoma". Articles from the last 10 years were selected and those that did not meet the inclusion criteria were excluded from the research, totaling 7 selected articles. Results P atients who were randomized to receive neoadjuvant pembrolizumab, with continued adjuvant therapy after surgery, had significantly prolonged survival compared to patients who were randomized to receive adjuvant post-surgical PD-1 blockade alone. Neoadjuvant PD-1 blockade was associated with up-regulation of T cells and interferon-γ-related gene expression, but with down-regulation of cell cycle-related gene expression within the tumor, which was not observed in patients receiving adjuvant therapy. isolated. Conclusion Neoadjuvant immunotherapy, through a PD-1 inhibitor, in patients with ArGB, results in positive biological effects, in addition to the clinical benefit of, on average, increasing overall survival considerably due in large part to the improvement of the immune response , with no noticeable adverse effects, thus being advantageous, although these results are early and the current studies are not very comprehensive. Larger studies are needed for greater reliabil ity and statistical relevance. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.